ARCHIVES

FDA Commissioner Says Swifter Drug Approvals, Enforcement Emphasis Characterize ‘Today’s FDA’

This article is from The Cancer Letter archive.

Vol. 18 No. 05 | January 31, 1992

Download PDF Visit The Full Archive

Related Articles

Reimbursement Policy By Philadelphia Blue Cross Further Explained

April 21, 1989

Illinois Congressman Calls For Full Bypass Budget Appropriation In cancer Prevention – $180 Million

February 22, 1991

FDA Grants Approvals to Lynparza, Blincyto, Xgeva, Gardasil 9 and Cyramza

December 26, 2014

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

NIH Authorization Set For Another Try; Women’s Cancers Are Targeted

July 10, 1992

Lasker Awards Resume; ASCO Fall Conference Scheduled For October

September 21, 1990